Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Skin Neoplasms × bempegaldesleukin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 6 Squamous Cell Carcinoma of Head and Neck 3 Carcinoma, Renal Cell 3 Triple Negative Breast Neoplasms 2 Sarcoma 2 Recurrence 2 Neoplasm Metastasis 2 Lymphoma, Non-Hodgkin 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Stomach Neoplasms 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Neuroblastoma 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Medulloblastoma 1 Lymphoma 1 Leukemia, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Glioma 1 Ependymoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Merkel Cell 1 Advanced Cancer 1

Interventions

pembrolizumab 19 aldesleukin 19 Nivolumab 19 Cyclophosphamide 18 Ipilimumab 16 fludarabine 14 Interleukin-2 14 fludarabine phosphate 12 cemiplimab 11 Radiotherapy 7 Fluorouracil 6 Dacarbazine 6 Vemurafenib 5 Radiation 5 Biopsy 5 Aminolevulinic Acid 5 dabrafenib 4 binimetinib 4 Temozolomide 4 Surgical Procedures, Operative 4 Sirolimus 4 Educational Status 4 trametinib 3 sonidegib 3 montanide ISA 51 3 encorafenib 3 avelumab 3 Sodium Chloride 3 Semaxinib 3 Photochemotherapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated

765 enrolled 13 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡